The long-term behavior and predictors of left ventricular hypertrophy in hemodialysis patients

Sim Kutlay1, Irem Dincer, Sule Sengül

  • 1Department of Nephrology, Ankara University School of Medicine, Ankara, Turkey.

Insights

Left ventricular hypertrophy (LVH) is not inevitable in hemodialysis (HD) patients. Aggressive treatment targeting predictors like C-reactive protein and blood pressure may regress left ventricular mass index (LVMI) and improve outcomes.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Left ventricular hypertrophy (LVH) is a common complication in patients undergoing hemodialysis (HD).
  • Understanding the long-term behavior of LVH and its predictors is crucial for managing cardiovascular risk in this population.

Purpose of the Study:

  • To evaluate the long-term behavior of LVH in HD patients.
  • To identify predictors of changes in left ventricular mass index (LVMI).

Main Methods:

  • 108 HD patients underwent annual echocardiography and 24-hour ambulatory blood pressure monitoring.
  • Left ventricular mass index (LVMI) was assessed, with LVH defined by specific thresholds for men and women.
  • Median follow-up was 50 months, with a median of 4 echocardiographic examinations per patient.

Main Results:

  • 75.9% of patients had LVH at baseline; LVH status changed in 40.7% during follow-up.
  • LVMI decreased by 8.0 g/m2 on average. Key predictors of LVMI change included C-reactive protein, baseline hemoglobin, and postdialysis systolic blood pressure.
  • 24-hour systolic blood pressure predicted baseline LVMI and LVH, while nighttime systolic blood pressure and C-reactive protein predicted final LVMI.

Conclusions:

  • Progressive LVH is not inevitable in hemodialysis patients.
  • Targeting identified predictors, such as C-reactive protein and blood pressure, may lead to regression of LVMI.
  • Interventions aimed at these predictors could potentially improve patient outcomes.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...